PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.

Abstract The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery.
PMID
Related Publications

The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.

Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer.

Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.

Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.

The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence.

Authors

Mayor MeshTerms
Keywords

Breast cancer

CA15-3

CEA

TPS

monitoring

surgery

Journal Title anticancer research
Publication Year Start




PMID- 29277810
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of
      Patients After Radical Surgery for Breast Cancer.
PG  - 465-469
AB  - AIM: The aim of this study was to evaluate the ability of tissue
      polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer
      antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the
      measurement of biomarkers is performed within 6 months after surgery. PATIENTS
      AND METHODS: Four hundred and seventy-two patients with breast cancer were
      evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after
      surgery. Disease recurrence was recorded between 7-12 months after surgery.
      Disease recurrence occurred in 60 patients, while 412 patients remained in
      recurrence-free status. RESULTS: TPS levels of the recurrence group differed
      statistically significantly in the first and sixth month after surgery compared
      to recurrence-free group (p=0.0339, AUC=0.6056; p<0.0001, AUC=0.7196). CEA and CA
      15-3 measurements did not achieve a statistically significant difference for any 
      month examined. CONCLUSION: TPS level in the sixth month after surgery is the
      best candidate biomarker to predict disease recurrence.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Svobodova, Sarka
AU  - Svobodova S
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic.
FAU - Kucera, Radek
AU  - Kucera R
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic [email protected]
FAU - Fiala, Ondrej
AU  - Fiala O
AD  - Department of Oncology and Radiotherapy, University Hospital and Faculty of
      Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
AD  - Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen,
      Czech Republic.
FAU - Marie, Karlikova
AU  - Marie K
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic.
FAU - Narsanska, Andrea
AU  - Narsanska A
AD  - Department of Surgery, University Hospital and Faculty of Medicine in Pilsen,
      Charles University, Pilsen, Czech Republic.
FAU - Zednikova, Ilona
AU  - Zednikova I
AD  - Department of Surgery, University Hospital and Faculty of Medicine in Pilsen,
      Charles University, Pilsen, Czech Republic.
FAU - Treska, Vladislav
AU  - Treska V
AD  - Department of Surgery, University Hospital and Faculty of Medicine in Pilsen,
      Charles University, Pilsen, Czech Republic.
FAU - Slouka, David
AU  - Slouka D
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic.
FAU - Milena, Rousarova
AU  - Milena R
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic.
FAU - Topolcan, Ondrej
AU  - Topolcan O
AD  - Department of Immunochemistry, University Hospital and Faculty of Medicine in
      Pilsen, Charles University, Pilsen, Czech Republic.
FAU - Finek, Jindrich
AU  - Finek J
AD  - Department of Oncology and Radiotherapy, University Hospital and Faculty of
      Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - Breast cancer
OT  - CA15-3
OT  - CEA
OT  - TPS
OT  - monitoring
OT  - surgery
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/10/20 00:00 [revised]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/465 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):465-469.